State Key Laboratory of Oncology in South China, Guangzhou, People's Republic of China.
PLoS One. 2012;7(12):e50936. doi: 10.1371/journal.pone.0050936. Epub 2012 Dec 13.
B-cell activation factor (BAFF) and BAFF-receptor (BAFF-R) play crucial roles in the viability and proliferation of malignant lymphoma cells. Limited information exists regarding expression profiles and the prognostic role of BAFF and BAFF-R in follicular lymphoma (FL). We sought to determine the expression profiles of BAFF and BAFF-R in FL and to evaluate the correlation of BAFF and BAFF-R expression with clinicopathologic characteristics and outcome of FL. Correlation between expression levels of BAFF detected by immunohistochemical (IHC) and serum levels of BAFF was also evaluated.
Paraffin-embedded specimens from 115 patients were immunohistochemically examined for BAFF and BAFF-R expression. Expression levels were dichotomized into low versus high categories based on immunostaining intensity. The correlation of BAFF and BAFF-R expression with clinicopathologic characteristics and patient outcome was assessed. Serum levels of BAFF in 35 of the 115 patients with IHC data were measured by Enzyme-linked Immunosorbent assay (ELISA).
BAFF and BAFF-R were expressed in 88.7% (102/115) and 87.8% (101/115) of the cases, respectively. BAFF expression was significantly correlated with only one clinicopathologic feature: Ann Arbor stage. No significant correlation was found between expression levels of BAFF detected by IHC and serum levels of BAFF detected by ELISA. High expression of BAFF-R, but not BAFF, was significantly correlated with inferior progression-free survival (PFS; P = 0.013) and overall survival (OS; P = 0.03). High expression of BAFF-R, bulky disease, and elevated lactate dehydrogenase were correlated with inferior PFS and OS in multivariate analysis. A prognostic scoring system incorporating these 3 risk factors identified 3 distinct prognostic groups with 5-year PFS of 59.4%, 41.9%, and 10.7% and OS of 91.3%, 79.7%, and 45.8%, respectively.
Most patients with FL variably express BAFF and BAFF-R. High expression of BAFF-R, but not BAFF, may be an independent risk factor for PFS and OS in FL.
B 细胞激活因子(BAFF)和 BAFF 受体(BAFF-R)在恶性淋巴瘤细胞的存活和增殖中发挥着至关重要的作用。关于滤泡性淋巴瘤(FL)中 BAFF 和 BAFF-R 的表达谱及其预后作用的信息有限。我们旨在确定 FL 中 BAFF 和 BAFF-R 的表达谱,并评估 BAFF 和 BAFF-R 表达与 FL 的临床病理特征和结局的相关性。还评估了免疫组化(IHC)检测到的 BAFF 表达水平与血清 BAFF 水平之间的相关性。
对 115 例患者的石蜡包埋标本进行 BAFF 和 BAFF-R 的免疫组化检查。根据免疫染色强度将表达水平分为低表达和高表达两类。评估 BAFF 和 BAFF-R 表达与临床病理特征和患者结局的相关性。对 115 例具有 IHC 数据的患者中的 35 例进行了血清 BAFF 水平的酶联免疫吸附测定(ELISA)。
BAFF 和 BAFF-R 的表达率分别为 88.7%(102/115)和 87.8%(101/115)。BAFF 的表达仅与一个临床病理特征显著相关:Ann Arbor 分期。通过 IHC 检测到的 BAFF 表达水平与通过 ELISA 检测到的血清 BAFF 水平之间无显著相关性。BAFF-R 的高表达,但不是 BAFF,与无进展生存期(PFS;P=0.013)和总生存期(OS;P=0.03)显著相关。在多变量分析中,BAFF-R 的高表达、肿块病和乳酸脱氢酶升高与 PFS 和 OS 不良相关。纳入这 3 个危险因素的预后评分系统将患者分为 3 个不同的预后组,5 年 PFS 分别为 59.4%、41.9%和 10.7%,OS 分别为 91.3%、79.7%和 45.8%。
大多数 FL 患者表达 BAFF 和 BAFF-R。BAFF-R 的高表达,但不是 BAFF,可能是 FL 患者 PFS 和 OS 的独立危险因素。